Granulocytic sarcoma: a systematic review.

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Granulocytic sarcoma (GS), also known as myeloid sarcoma, is a rare extramedullary tumor composed of immature granulocytic cells.
• GS is frequently associated with acute myeloid leukemia (AML) and can occur in myeloproliferative disorders like chronic myeloid leukemia and myelodysplastic syndromes.
• Isolated or primary GS, diagnosed when bone marrow biopsy shows no other hematologic malignancies, presents a diagnostic and therapeutic challenge.

Purpose of the Study:

• To review the characteristics, diagnosis, and current treatment strategies for granulocytic sarcoma.
• To highlight the diagnostic methods and the challenges in managing primary or nonleukemic GS.
• To emphasize the need for further research and clinical trials to establish treatment guidelines.

Main Methods:

• Review of existing literature on granulocytic sarcoma, focusing on its clinical presentation, diagnosis, and treatment.
• Analysis of diagnostic techniques including biopsy, H&E staining, immunohistochemistry, flow cytometry, FISH, and molecular analysis.
• Evaluation of current therapeutic approaches, including surgery, systemic chemotherapy, radiotherapy, and hematopoietic stem cell transplantation.

Main Results:

• Granulocytic sarcoma most commonly affects soft tissues, bone, peritoneum, and lymph nodes, with symptoms arising from mass effect or organ dysfunction.
• Diagnosis relies on tumor biopsy, confirming immature granulocytic cells via various pathological methods.
• Treatment remains unclear, with surgery for localized issues, systemic therapy crucial to prevent AML progression, and unclear roles for consolidation therapies, stem cell transplantation, and radiotherapy.

Conclusions:

• Granulocytic sarcoma is a rare extramedullary tumor often linked to myeloid malignancies.
• Optimal treatment strategies for primary GS are not well-defined, necessitating systemic therapy to prevent progression to AML.
• Further prospective studies and clinical trials are essential to develop evidence-based guidelines for managing granulocytic sarcoma.